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Background: Umeclidinium (UMEC; long-acting muscarinic antagonist [LAMA])/vilanterol (VI;
long-acting beta2-agonist [LABA]) and fluticasone propionate/salmeterol (FP/SAL) (inhaled
corticosteroid/LABA) are approved maintenance therapies for chronic obstructive pulmonary
disease (COPD). Two studies compared efficacy and safety of UMEC/VI with FP/SAL in patients
with moderate-to-severe COPD with no exacerbations in the previous year.
Methods: In these 12-week, multicenter, double-blind, parallel-group, double-dummy trials,
randomized (1:1) patients received once-daily UMEC/VI 62.5/25 mcg or twice-daily FP/SAL
250/50 mcg (DB2114930 n Z 353 and 353; DB2114951 n Z 349 and 348, respectively; intent-
to-treat). Endpoints included 0e24 h weighted mean (wm) forced expiratory volume in 1 s
(FEV1) (Day 84; primary), trough FEV1 (Day 85; secondary), other lung function endpoints,9) 966 2531; fax: þ1 (919) 966 7013.
@med.unc.edu (J.F. Donohue), sally.d.worsley@gsk.com (S. Worsley), chang-qing.2.zhu@gsk.com
L. Hardaker), alison.x.church@gsk.com (A. Church).
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lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
nd/4.0/).
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Results: UMEC/VI demonstrated statistically significant, clinically meaningful improvements in
lung function measures versus FP/SAL. For 0e24 h wmFEV1 (Day 84), improvements with
UMEC/VI versus FP/SAL were 74 mL (95% confidence interval [CI]: 38e110; DB2114930)
and 101 mL (63e139; DB2114951) (both p < 0.001). Trough FEV1 improvements were 82 mL
(45e119) and 98 mL (59e137) (both p < 0.001) for UMEC/VI versus FP/SAL, respectively. Both
treatments demonstrated similar, clinically meaningful improvements from baseline in dys-
pnea (Transition Dyspnea Index focal score >1 unit) and QoL (St George’s Respiratory Question-
naire Total score >4-unit decrease) in both studies with no statistical differences between
treatments. Adverse event rates were similar: 26 and 30% UMEC/VI; 27 and 31% FP/SAL.
Conclusions: Once-daily UMEC/VI 62.5/25 mcg over 12 weeks resulted in statistically
significant, clinically meaningful improvements in lung function versus twice-daily FP/SAL
250/50 mcg in patients with moderate-to-severe COPD with infrequent exacerbations. Both
treatments improved dyspnea and QoL.
Clinical trial registration: DB2114930/NCT01817764; DB2114951/NCT01879410.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Inhaled corticosteroid (ICS)/long-acting beta2 agonist
(LABA) combinations and long-acting muscarinic antagonist
(LAMA)/LABA combinations are two treatments for patients
with chronic obstructive pulmonary disease (COPD) which
have both been shown to improve airflow obstruction [1].
Additionally, ICS/LABA combinations have also been shown
to reduce exacerbations in patients with a history of ex-
acerbations [2]. As long-term ICS use may be associated
with adverse events (AEs) [3,4], the ICS benefits versus risks
should be considered when treating particular groups of
patients with COPD. Guidelines recommend treatment with
ICS/LABA for patients with COPD with severe airflow
impairment and/or frequent exacerbations, i.e. patients
with GOLD C (non-symptomatic) and D (symptomatic) COPD
[1]. However, patients with GOLD B disease who have a
lower risk of exacerbation are often prescribed ICS/LABAs
[5]. LAMA/LABA combinations are currently recommended
as a treatment option for patients with GOLD B disease as
well as those with GOLD C and D disease [1]. However, few
studies have compared the treatment benefits of ICS/LABAs
and LAMA/LABAs in patients with COPD with symptomatic,
moderate-to-severe COPD with an infrequent exacerbation
history (GOLD B and a subset of GOLD D).
Umeclidinium (UMEC, a LAMA) combined with vilanterol
(VI, a LABA) is approved in several countries, including the
USA and EU, as a once-daily (62.5/25 mcg) maintenance
COPD treatment [6,7]. In patients with COPD, lung function
was statistically significantly improved with UMEC/VI versus
placebo [8,9] and versus monotherapy treatments [8e10].
UMEC/VI and monotherapy treatments were also well
tolerated [8e11]. The ICS/LABA combination fluticasone
propionate/salmeterol (FP/SAL) at a dose of 250/50 mcg is
approved in the USA, but not Europe, as a twice-daily
maintenance COPD medication [12]. Statistically signifi-
cant improvements in lung function and reductions in ex-
acerbations have been demonstrated with FP/SAL versus
placebo and monotherapy in moderate-to-severe COPD
[13e15].Three studies have compared UMEC/VI with FP/SAL; one
with 500/50 mcg FP/SAL [16] and two with 250/50 mcg
FP/SAL described herein. The primary objectives of these
studies were to investigate whether the once-daily LAMA/
LABA combination UMEC/VI 62.5/25 mcg would show
greater improvements in lung function, dyspnea and quality
of life (QoL) than twice-daily FP/SAL 250/50 mcg over
12 weeks in patients with symptomatic moderate-to-severe
COPD with a history of infrequent COPD exacerbations.
Materials and methods
Patients
All patients provided written informed consent. These
studies were approved by local ethics committees
(Appendix A, Table A.1) and conducted in accordance with
the Declaration of Helsinki [17] and Good Clinical Practice
guidelines [18]. For both studies, key inclusion criteria were
patients with symptomatic (dyspnea score 2, modified
Medical Research Council [mMRC] Dyspnea Scale),
moderate-to-severe COPD (forced expiratory volume in 1 s
[FEV1] 30% and 70%) without a documented history of an
exacerbation (COPD symptoms requiring treatment with
either oral corticosteroids, antibiotics and/or hospitaliza-
tion) in the year before screening. See Appendix B for
further details.
Study design, randomization and treatment
Both studies (Fig. 1; see Appendix B for study visit details)
were multicenter, randomized, double-blind, double-
dummy, parallel-group trials (GSK/www.clinicaltrials.gov
numbers: DB2114930/NCT01817764, DB2114951/
NCT01879410). DB2114930 was conducted between 26
March 2013 and 26 October 2013 in 63 centers in seven
countries (Argentina, Chile, Greece, Peru, Romania,
Ukraine, USA). DB2114951 was conducted in 71 centers in
seven countries (Chile, Mexico, Norway, Romania, Russian
Figure 1 Study design. FP/SAL, fluticasone propionate/
salmeterol; ITT, intent-to-treat; UMEC, umeclidinium; V, clinic
visit; VI, vilanterol.
872 J.F. Donohue et al.Federation, South Africa, USA) between 13 June 2013 and
9 January 2014.
A central randomization schedule was generated using a
validated computer system (RandAll; GSK, Brentford, UK).
A registration and medication ordering system (GSK,
Brentford, UK) was used to randomize patients 1:1 to either
UMEC/VI or FP/SAL. Study personnel and patients were
blinded to study medication.
Discontinuation requirements of previous medication
are shown in Table B.1. Randomized patients received
either once-daily UMEC/VI 62.5/25 mcg (delivered doses
55/22 mcg, morning) via the ELLIPTA1 dry powder inhaler
(DPI) and twice-daily placebo (DISKUS2) or twice-daily
FP/SAL 250/50 mcg via the DISKUS and once-daily placebo
(ELLIPTA DPI) for 12 weeks. Inhaler dose counters were
reviewed at each visit to assess compliance.
Outcome assessments
Endpoints were nearly identical for both studies (Appendix
B); inspiratory capacity (IC) was only evaluated in
DB2114930.
Efficacy (lung function) assessments
Primary and secondary endpoints were 0e24 h weighted
mean (wm) FEV1 (Day 84) and trough FEV1 (Day 85),
respectively. Other lung function endpoints included:
0e24 h serial FEV1 (Day 84); peak FEV1 over 0e6 h post-dose
(Days 1 and 84); trough FEV1 (Days 28, 56 and 84); time to
onset (FEV1 100 mL increase above baseline during 0e6 h
post-dose, Day 1); proportion of patients achieving an in-
crease from baseline in: a) trough FEV1 100 mL (Day 85),
b) FEV1 12% and 200 mL during 0e6 h post-dose (Day 1)
and c) FEV1 100 mL at 5 and 15 min and 1, 3 and 6 h post-
dose (Day 1; post-hoc analyses); 0e24 h wm forced vital
capacity (FVC) at Day 84; trough FVC (Day 85); 0e6 wm FVC
(Days 1 and 84); IC (Day 84; DB2114930 only).1 ELLIPTA is a trademark of the GSK group of companies.
2 DISKUS is a trademark of the GSK group of companies.Health outcomes and symptomatic endpoints
Dyspnea and QoL were assessed using the Transition Dys-
pnea Index (TDI) (Days 28, 56 and 84; interviewer-
administered form) and the St George’s Respiratory Ques-
tionnaire (SGRQ) for patients with COPD (baseline, Days 28
and 84), respectively. Rescue medication use was recorded.
The EuroQol-5D (EQ-5D) questionnaire and the COPD
Assessment Test (CAT) were used to assess health outcomes
and COPD-related health status, respectively, at randomi-
zation/baseline and Day 84.
Safety evaluations
Safety and tolerability included monitoring AEs (coded
using the Medical Dictionary for Regulatory Activities),
COPD exacerbations (an acute worsening of COPD symp-
toms requiring use of antibiotics, systemic corticosteroids,
and/or emergency treatment or hospitalization) and vital
signs throughout both studies.
Statistical analyses
Accounting for 0e24 h wmFEV1 variability and predicted
drop-out rate, in each study 355 randomized patients/
group would provide 284 evaluable patients/group to
detect a 60 mL treatment difference in 0e24 h wmFEV1
with 90% power (Appendix B).
An analysis of covariance model (covariates: baseline
FEV1, smoking status and treatment) was used to analyze
0e24 h wmFEV1 (Day 84). Trough FEV1 (Day 85) was
analyzed using a mixed model for repeated measures
analysis (covariates: baseline FEV1, smoking status, day,
treatment, day by baseline interaction and day by treat-
ment interaction, where day is nominal). See Appendix B
for further analyses.
All analyses were conducted for all randomized patients
who took at least one dose of study medication (intent-to-
treat [ITT] population). A step-down, closed-testing pro-
cedure was used to account for multiplicity across primary
and secondary endpoints (Appendix B).
Results
Study populations
Of 921 patients enrolled, 867 were screened, 707
were randomized (Fig. 2a) and 634 completed DB2114930
(UMEC/VI: 319; FP/SAL: 315). For DB2114951, of 966 patients
enrolled, 910 were screened, 700 were randomized
(Fig. 2b) and 638 completed the study (UMEC/VI: 326;
FP/SAL: 312). Fig. 2 summarizes withdrawal reasons.
Within each study, patient demographics and charac-
teristics were well balanced between groups (Table 1),
though no formal statistical comparisons were performed.
Overall, 50% of patients had moderate COPD (GOLD stage II)
and 50% had severe COPD (GOLD stage III), while mean %
predicted FEV1 was w50% and mean SGRQ score was w47.
COPD medication pre-enrollment is summarized in
Appendix B.
Figure 2 Flow diagram for disposition of patients (CONSORT). a) DB2114930. b) DB2114951. FP/SAL, fluticasone propionate/
salmeterol; ITT, intent-to-treat; UMEC, umeclidinium; VI, vilanterol. *One patient was randomized to UMEC/VI but withdrew
consent prior to the administration of study medication. **Three patients were randomized in error; two of these patients were
run-in failures and the third patient was a screen failure; none of these patients received study treatment.
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Table 1 Patient demographics and lung function at baseline (ITT population).
DB2114930 DB2114951
UMEC/VI 62.5/25
mcg (N Z 353)
FP/SAL 250/50
mcg (N Z 353)
Total
(N Z 706)
UMEC/VI 62.5/25
mcg (N Z 349)
FP/SAL 250/50
mcg (N Z 348)
Total (N Z 697)
Age, mean ± SD, years 62.5  9.05 63.0  8.91 62.8  8.97 63.2  8.57 64.0  8.53 63.6  8.55
Sex: male, n (%) 253 (72) 244 (69) 497 (70) 264 (76) 264 (76) 528 (76)
BMI, mean ± SD (range), kg/m2a 27.55  4.908
(16.9e45.3)
27.30  5.560
(16.2e53.1)
27.42  5.242
(16.2e53.1)
27.40  6.139
(15.6e62.3)
26.74  5.559
(15.9e49.4)
27.07  5.861
(15.6e62.3)
Race, n (%)
White 341 (97) 343 (97) 684 (97) 317 (91) 326 (94) 643 (92)
African American/African heritage 4 (1) 3 (<1) 7 (<1) 18 (5) 13 (4) 31 (4)
American Indian or Alaska native 5 (1) 5 (1) 10 (1) 7 (2) 2 (<1) 9 (1)
Asian 3 (<1) 2 (<1) 5 (<1) 4 (1) 2 (<1) 6 (<1)
American Indian or Alaska native & White 0 0 0 3 (<1) 5 (1) 8 (1)
Smoking history and status
Current smoker, n (%) 159 (45) 145 (41) 304 (43) 179 (51) 184 (53) 363 (52)
Years smoked, mean  SD (range) 36.5  11.85
(10e66)
37.0  11.36
(10e65)
36.7  11.60
(10e66)
39.1  10.58
(10e67)
39.6  10.61
(10e66)
39.4  10.59
(10e67)
No. cigarettes/day, mean  SD (range) 23.6  10.69
(4e65)
22.5  10.75
(6e80)
23.1  10.73
(4e80)
22.7  10.41
(5e70)
22.4  10.44
(5e100)
22.5  10.42
(5e100)
Smoking pack years, mean  SD (range) 43.2  25.27
(10e162)
41.7  24.35
(10e159)
42.5  24.80
(10e162)
43.8  22.19
(10e135)
44.5  26.13
(10e285)
44.1  24.22
(10e285)
COPD history
Duration of COPD, n (%), years
<1 11 (3) 19 (5) 30 (4) 23 (7) 20 (6) 43 (6)
1e<5 114 (32) 123 (35) 237 (34) 133 (38) 127 (36) 260 (37)
5e<10 124 (35) 122 (35) 246 (35) 100 (29) 103 (30) 203 (29)
10 104 (29) 89 (25) 193 (27) 93 (27) 98 (28) 191 (27)
COPD type, n (%)b
Chronic bronchitis 264 (75) 271 (77) 535 (76) 250 (72) 248 (72) 498 (72)
Emphysema 210 (59) 208 (59) 418 (59) 213 (61) 228 (66) 441 (64)
Screening lung function, mean (SD)
Pre-albuterol FEV1, L
c 1.311 (0.4077) 1.333 (0.4539) 1.322 (0.4312) 1.338 (0.4412) 1.332 (0.4651) 1.335 (0.4530)
Post-albuterol FEV1, L
d 1.443 (0.4212) 1.459 (0.4661) 1.451 (0.4440) 1.492 (0.4463) 1.485 (0.4747) 1.488 (0.4603)
Pre-albuterol FEV1/FVC, (%FEV1)
c 47.5 (10.61) 46.8 (10.78) 47.2 (10.69) 47.3 (10.73) 47.0 (10.72) 47.2 (10.71)
Post-albuterol FEV1/FVC, (%FEV1)
d 48.6 (10.71) 48.3 (10.82) 48.5 (10.76) 48.3 (10.75) 48.0 (10.55) 48.2 (10.65)
Post-albuterol percent predicted FEV1, %
d 49.2 (10.82) 49.6 (10.88) 49.4 (10.85) 49.4 (10.81) 49.5 (10.87) 49.5 (10.83)
Percent reversibility to albuterol,
%c,d
11.5 (12.61) 11.1 (13.45) 11.3 (13.03) 13.2 (14.08) 13.4 (13.59) 13.3 (13.83)
Reversibility to albuterol,
mLc,d
132.5 (139.39) 126.7 (148.52) 129.6 (143.96) 152.9 (152.43) 152.8 (164.79) 152.9 (158.62)
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GOLD stage (percent predicted FEV1) and reversibility, n (%)
d
Stage I (80%) 0 0 0 0 0 0
Stage II (50% to < 80%) 170 (48) 177 (50) 347 (49) 173 (50) 173 (50) 346 (50)
Stage III (30% to < 50%) 182 (52) 175 (50) 357 (51) 176 (50) 175 (50) 351 (50)
Stage IV (<30%) 0 0 0 0 0 0
Reversible to albuterolc 92 (26) 97 (28) 189 (27) 120 (34) 119 (34) 239 (34)
mMRC dyspnea scale, median (range) 2.0 (2e4) 2.0 (2e4) 2.0 (2e4) 2.0 (2e4) 2.0 (2e4) 2.0 (2e4)
BDI focal score, mean (SD)e 6.1 (2.13) 6.1 (1.91) e 6.2 (2.00) 6.0 (2.08) e
Health-related QoL/health outcomes, mean (SD)
SGRQ Total scoref 46.17 (17.039) 45.79 (17.340) e 47.22 (17.511) 48.36 (17.625) e
EQ-5D utility scoreg 0.70 (0.228) 0.68 (0.243) e 0.70 (0.229) 0.70 (0.225) e
CAT score 17.67 (7.016) 17.80 (7.130) e 17.88 (7.562) 18.97 (7.507) e
BDI, Baseline Dyspnea Index; BMI, body mass index; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; EQ-5D, EuroQol-5D; FEV1, forced expiratory volume in 1 s;
FP/SAL, fluticasone propionate/salmeterol; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; ITT, intent-to-treat; mMRC, modified Medical
Research Council; No., number; SD, standard deviation; SGRQ, St. George’s Respiratory Questionnaire for COPD patients; UMEC, umeclidinium; VI, vilanterol.
a n Z 346 (UMEC/VI), 347 (FP/SAL) and 693 (Total) in DB2114951.
b Patients could select chronic bronchitis, emphysema or both.
c n Z 348 (UMEC/VI) and 696 (Total) in DB2114951.
d n Z 352 (UMEC/VI and FP/SAL) and 704 (Total) in DB2114930.
e n Z 346 (UMEC/VI and FP/SAL) in DB2114930, and 345 (UMEC/VI) and 343 (FP/SAL) in DB2114951.
f n Z 347 (UMEC/VI) and 351 (FP/SAL) in DB2114930, and 344 (UMEC/VI) and 343 (FP/SAL) in DB2114951.
g n Z 352 (UMEC/VI) in DB2114930.
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Table 2 Results from the analyses of the primary, secondary and selected other endpoints (ITT population).
Endpoint DB2114930 DB2114951
UMEC/VI 62.5/25
mcg (N Z 353)
FP/SAL 250/50
mcg (N Z 353)
UMEC/VI 62.5/25
mcg (N Z 349)
FP/SAL 250/50
mcg (N Z 348)
Primary endpoint
0e24 h wmFEV1 on Day 84, L
N 315 310 322 311
LS mean (SE) 1.494 (0.0130) 1.420 (0.0131) 1.533 (0.0137) 1.432 (0.0139)
LS mean (SE) change from baseline 0.165 (0.0130) 0.091 (0.0131) 0.213 (0.0137) 0.112 (0.0139)
Treatment difference (95% CI) 0.074 (0.038e0.110)
p < 0.001
0.101 (0.063e0.139)
p < 0.001
Secondary endpoint
Trough FEV1 on Day 85, L
na 341 339 335 336
nb 317 312 323 311
LS mean (SE) 1.488 (0.0133) 1.406 (0.0134) 1.499 (0.0138) 1.401 (0.0140)
LS mean (SE) change from baseline 0.154 (0.0133) 0.072 (0.0134) 0.185 (0.0138) 0.087 (0.0140)
Treatment difference (95% CI) 0.082 (0.045e0.119)
p < 0.001
0.098 (0.059e0.137)
p < 0.001
Other endpoints (selected)
Peak FEV1 0e6 h, L
Day 1
na 353 351 346 348
nb 353 351 346 347
LS mean (SE) 1.586 (0.0086) 1.521 (0.0087) 1.601 (0.0089) 1.544 (0.0089)
LS mean (SE) change from baseline 0.258 (0.0086) 0.193 (0.0087) 0.286 (0.0089) 0.230 (0.0089)
Treatment difference (95% CI) 0.064 (0.040e0.089)
p < 0.001
0.056 (0.032e0.081)
p < 0.001
Day 84
na 353 351 346 348
nb 320 314 325 312
LS mean (SE) 1.642 (0.0141) 1.536 (0.0142) 1.685 (0.0146) 1.563 (0.0148)
LS mean (SE) change from baseline 0.314 (0.0141) 0.208 (0.0142) 0.371 (0.0146) 0.248 (0.0148)
Treatment difference (95% CI) 0.107 (0.067e0.146)
p < 0.001
0.122 (0.081e0.163)
p < 0.001
Time to onset on Day 1 (increase in 0e6 h post-dose FEV1 ‡ 100 mL above baseline)
N 353 351 346 347
Median time to onset, min 18 63 16 58
Hazard ratio (95% CI) 1.4 (1.2e1.6)
p < 0.001
1.6 (1.3e1.9)
p < 0.001
Proportion of patients achieving an increase in FEV1 ‡ 100 mL above baseline at 5 min post-dose on
Day 1 (post-hoc analysis)
N 344 344 339 345
Increase, n (%) 123 (36) 86 (25) 160 (47) 107 (31)
No increase, n (%) 221 (64) 258 (75) 179 (53) 238 (69)
Odds ratio (95% CI) 1.66 (1.20e2.31)
p Z 0.003
1.98 (1.45e2.72)
p < 0.001
Proportion of patients achieving an increase in 0e6 h post-dose FEV1 ‡ 12% and ‡200 mL above baseline on Day 1
N 353 351 347 347
Increase, n (%) 198 (56) 129 (37) 216 (62) 173 (50)
No increase, n (%) 155 (44) 222 (63) 131 (38) 174 (50)
Odds ratio (95% CI) 2.18 (1.61e2.95)
p < 0.001
1.66 (1.23e2.24)
p Z 0.001
Proportion of patients achieving an increase in trough FEV1 ‡ 100 mL above baseline on Day 85
N 318 312 324 311
Increase, n (%) 189 (59) 130 (42) 207 (64) 141 (45)
No increase, n (%) 129 (41) 182 (58) 117 (36) 170 (55)
2.04 (1.48e2.81)
p < 0.001
2.18 (1.58e3.00)
p < 0.001
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Table 2 (continued )
Endpoint DB2114930 DB2114951
UMEC/VI 62.5/25
mcg (N Z 353)
FP/SAL 250/50
mcg (N Z 353)
UMEC/VI 62.5/25
mcg (N Z 349)
FP/SAL 250/50
mcg (N Z 348)
Trough IC on Day 84, L
N 320 316 e e
LS mean (SE) 2.248 (0.0188) 2.149 (0.0190) e e
LS mean (SE) change from baseline 0.126 (0.0188) 0.027 (0.0190) e e
Treatment difference (95% CI) 0.099 (0.046e0.151)
p < 0.001
e
Analysis of the primary endpoint was performed using ANCOVA with covariates of baseline FEV1, smoking status and treatment. Analysis
of secondary endpoint was by MMRM analysis including covariates of baseline FEV1, smoking status, day, treatment, day by baseline and
day by treatment interactions, where day is nominal.
CI, confidence interval; FEV1, forced expiratory volume in 1 s; FP/SAL, fluticasone propionate/salmeterol; IC, inspiratory capacity; ITT,
intent-to-treat; LS, least squares; MRMM, mixed-effect model repeated measure model; SE, standard error; UMEC, umeclidinium; VI,
vilanterol; wm, weighted mean.
a Number of patients with analyzable data for 1 or more time points.
b Number of patients with analyzable data at the current time point.
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was 98.5% (4.9%) and 104.1% (120.1%) for UMEC/VI and
98.1% (7.1%) and 105.9% (150.3%) for FP/SAL in DB2114930
and DB2114951, respectively.
Efficacy
Primary and secondary endpoints
In both studies, UMEC/VI demonstrated statistically signif-
icant and clinically meaningful improvements in least
squares (LS) mean change from baseline in 0e24 h wmFEV1
(primary endpoint) versus FP/SAL on Day 84 (Table 2;
p < 0.001). This finding is supported by the statistically
significant improvement in LS mean change from baseline in
FEV1 at all time points for UMEC/VI versus FP/SAL (Fig. 3;
except at 18 h in DB2114930). UMEC/VI gave clinically
meaningful and statistically significant (p < 0.001) im-
provements in LS mean change from baseline in trough FEV1
on Day 85 (secondary endpoint) versus FP/SAL (Table 2,
Fig. 4). Similar improvements were seen on Days 28, 56 and
84 (Fig. 4) in both studies.
In descriptive summaries, raw mean change from base-
line for both endpoints was greater with UMEC/VI than with
FP/SAL regardless of GOLD subgroup. For UMEC/VI, the
mean change was slightly greater in patients with GOLD II
versus GOLD III COPD (Table B.2) in both studies for both
endpoints, and for FP/SAL in DB2114930. In DB2114951,
with FP/SAL the mean change was slightly lower in patients
with GOLD II versus GOLD III COPD for both endpoints (Table
B.2).
Other lung function endpoints
Statistically significant improvements in LS mean change
from baseline in peak FEV1 0e6 h occurred with UMEC/VI
versus FP/SAL on Days 1 (p < 0.001) and 84 (p < 0.001) in
both studies (Table 2).
Median time to onset on Day 1 was significantly
(p < 0.001 both studies) shorter with UMEC/VI versusFP/SAL (Table 2). For both studies, the proportion of pa-
tients achieving an increase in FEV1 100 mL above base-
line was significantly greater with UMEC/VI versus FP/SAL
at 5 min (Table 2), 15 min, 1, 3 and 6 h post-dose (Table B.3).
Patients receiving UMEC/VI had statistically significantly
greater odds than those treated with FP/SAL of achieving
an increase in FEV1 12% and 200 mL above baseline
during 0e6 h post-dose on Day 1 versus not achieving this
increase (p < 0.001 DB2114930; pZ 0.001 DB2114951), and
of achieving an increase in trough FEV1 100 mL above
baseline on Day 85 versus not achieving this increase
(p < 0.001 both studies; Table 2).
In both studies, UMEC/VI demonstrated statistically sig-
nificant improvements in FVC endpoints versus FP/SAL
(Table B.4). In DB2114930, UMEC/VI statistically signifi-
cantly improved the LS mean change from baseline in
trough IC on Day 84 versus FP/SAL (p < 0.001; Table 2).
Health outcomes and symptomatic endpoints
In both studies, UMEC/VI and FP/SAL treatment resulted in
clinically meaningful TDI focal scores (>1 unit) and im-
provements in mean SGRQ total scores (4 unit decrease
from baseline) at all time points (Table B.5), except for
FP/SAL on Day 28 in DB2114951. No statistically significant
treatment differences were seen between UMEC/VI and
FP/SAL in either endpoint at any time point (Table B.5),
except on Day 28 in DB2114951 where the difference in
SGRQ total score was 1.95 (pZ 0.026) favoring UMEC/VI.
The LS mean change from baseline in the mean number
of puffs of rescue medication/day over 12 weeks was sta-
tistically significantly reduced with UMEC/VI versus FP/SAL
in DB2114951 and similar between treatment groups in
DB2114930 (Table B.6). The change from baseline in per-
centage of rescue-free days over 12 weeks was similar be-
tween groups within each study (Table B.6).
No treatment differences were seen in the mean change
from baseline on Day 84 in the EQ-5D utility score or in CAT
scores within each study (Table B.7).
Figure 3 LS mean (95% CI) change from baseline in FEV1 (L)
over 0e24 h on Day 84 (ITT population). CI, confidence inter-
val; FEV1, forced expiratory volume in 1 s; FP/SAL, fluticasone
propionate/salmeterol; ITT, intent-to-treat; LS, least squares;
UMEC, umeclidinium; VI, vilanterol.
Figure 4 LS mean (95% CI) change from baseline in trough
FEV1 (L) at Days 28, 56, 84 and 85 (ITT population). CI, confi-
dence interval; FEV1, forced expiratory volume in 1 s; FP/SAL,
fluticasone propionate/salmeterol; ITT, intent-to-treat; LS,
least squares; UMEC, umeclidinium; VI, vilanterol.
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In both studies, UMEC/VI and FP/SAL were well tolerated,
with no marked differences in AE profiles between these
treatments (Table 3). The most common AEs in both groups
were headache and nasopharyngitis in both studies. The
number of patients with cardiac AEs (UMEC/VI n Z 4;
FP/SAL nZ 7 [DB2114930]; UMEC/VI nZ 10; FP/SAL nZ 7
[DB2114951]), or pneumonia (UMEC/VI nZ 1; FP/SAL nZ 4
[DB2114930]; UMEC/VI n Z 2; FP/SAL n Z 4 [DB2114951])
was very low in both studies. Other safety findings are
summarized in Appendix B.Discussion
This manuscript reports for the first time comparative ef-
ficacy data for UMEC/VI versus FP/SAL in patients with
COPD. In these two large-scale studies, once-daily UMEC/VI
(62.5/25 mcg) resulted in consistent, statistically signifi-
cant and clinically meaningful improvements in FEV1 andFVC measures at various time points over 12 weeks versus
twice-daily FP/SAL (250/50 mcg) in patients with symp-
tomatic moderate-to-severe COPD and infrequent exacer-
bations. Clinically meaningful improvements in dyspnea
and QoL occurred with both treatments. Both combinations
were well tolerated.
GOLD-recommended COPD treatments are currently
based on four patient categories [1]. However, GOLD groups
are heterogeneous [19], which challenges current COPD
classifications [20]. Defining the most appropriate man-
agement for individual patients is of clinical interest. We
explored the potential role of a non-ICS containing bron-
chodilator combination in patients with moderate-to-
severe COPD with dyspnea symptoms at baseline and
without a history of exacerbations by comparing the effi-
cacy and safety of UMEC/VI with FP/SAL. In both studies,
z50% of patients met full GOLD B criteria and z50% met
GOLD D criteria for lung function and symptoms [1].
Compared with FP/SAL, UMEC/VI demonstrated statis-
tically and clinically meaningful improvements in lung
function endpoints in the overall populations. Based on
descriptive summaries, wmFEV1 and trough FEV1
Table 3 Summary of incidence of on-treatment AEs, SAEs, AEs of special interest, most frequent AEs and COPD exacerbation
(ITT population).
DB2114930 DB2114951
UMEC/VI 62.5/25
mcg (N Z 353)
FP/SAL 250/50
mcg (N Z 353)
UMEC/VI 62.5/25
mcg (N Z 349)
FP/SAL 250/50
mcg (N Z 348)
AEs, n (%)
Any 93 (26) 96 (27) 104 (30) 108 (31)
Drug-related 6 (2) 7 (2) 6 (2) 20 (6)
Leading to permanent discontinuation or withdrawal 7 (2) 10 (3) 9 (3) 14 (4)
Serious AEs, n (%)
Any 6 (2) 10 (3) 11 (3) 13 (4)
Drug-related 1 (<1) 0 0 1 (<1)
Fatal 0 1 (<1) 2 (<1) 3 (<1)
AEs of special interest, n (%)
Cardiac arrhythmias 2 (<1) 2 (<1) 4 (1) 5 (1)
Cardiac failure 0 1 (<1) 4 (1) 2 (<1)
Cardiac ischemia 1 (<1) 3 (<1) 2 (<1) 2 (<1)
Stroke 1 (<1) 2 (<1) 0 0
Pneumonia 1 (<1) 4 (1) 2 (<1) 4 (1)
LRTI (excluding pneumonia) 0 3 (<1) 3 (<1) 2 (<1)
AEs occurring in ‡3% patients in any treatment group, n (%)
Headache 23 (7) 17 (5) 24 (7) 23 (7)
Nasopharyngitis 16 (5) 8 (2) 14 (4) 6 (2)
COPD exacerbations, n (%) 12 (3) 11 (3) 9 (3) 11 (3)
AE, adverse event; COPD, chronic obstructive pulmonary disease; FP/SAL, fluticasone propionate/salmeterol; ITT, intent-to-treat; LRTI,
lower respiratory tract infection; UMEC, umeclidinium; VI, vilanterol.
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in GOLD II and III subgroups. These findings confirm the
preliminary results reported for a similar study comparing
once-daily UMEC/VI (62.5/25 mcg) with twice-daily FP/SAL
at 500/50 mcg [16]. All three studies demonstrated that
patients with symptomatic COPD without a history of ex-
acerbations may achieve greater lung function benefits
with UMEC/VI versus FP/SAL.
Our findings confirm and extend those of previous
studies comparing a LAMA/LABA combination with FP/SAL
[21,22]. Lung function was significantly improved with
tiotropium (18 mcg once daily)/formoterol (12 mcg twice
daily) over 6 weeks versus twice-daily FP/SAL (500/50 mcg)
in patients with moderate COPD [21]. Once-daily QVA149
(glycopyrronium/indacaterol) significantly improved lung
function versus twice-daily FP/SAL (500/50 mcg) in patients
with moderate-to-severe COPD without exacerbations in
the prior 12 months in the 26-week ILLUMINATE study [22].
Key differences between our studies and ILLUMINATE were
the recruitment of more patients with severe air flow
obstruction at baseline (z50% versus 18%, respectively),
and a strict inclusion criterion of an mMRC Dyspnea Scale
score 2; thus, we evaluated patients with symptomatic
moderate-to-severe COPD. Collectively, these studies
involving several LAMA/LABA combinations all demonstrate
the potential clinical benefits of such a combination versus
the commonly used ICS/LABA regimen, FP/SAL, in patients
with symptomatic moderate-to-severe COPD with infre-
quent exacerbations.
In both studies, clinically meaningful improvements in
symptomatic endpoints and health outcomes wereachieved with both treatments, although there were no
statistically significant differences between UMEC/VI and
FP/SAL despite the greater lung function improvements in
response to UMEC/VI versus FP/SAL. As improved lung
function is often associated with beneficial effects on
symptomatic and QoL outcomes, the lack of a statistically
significant improvement in QoL with UMEC/VI over FP/SAL
is surprising. However, substantial improvements in TDI and
SGRQ scores were observed for both UMEC/VI and FP/SAL
compared with baseline, and other studies with active
treatments have also shown lung function improvements
with one treatment versus another without treatment dif-
ferences in SGRQ. For example, in the 26-week ILLUMINATE
trial, once-daily QVA statistically significantly improved
lung function versus FP/SAL, with statistically significant
improvements in TDI that failed to reach the minimal
clinically important difference of 1 unit. Additionally, no
difference was observed in SGRQ between QVA149 and
FP/SAL [22]. The similar effects of FP/SAL and UMEC/VI on
these outcomes in our studies might reflect that the current
tools (e.g. QoL questionnaires) are not designed to detect
differences between two active treatments.
The validity of both studies in comparing lung function
changes in response to UMEC/VI versus FP/SAL is confirmed
by the changes from baseline in lung function which are
consistent with previous studies evaluating UMEC/VI [8e10]
and FP/SAL [13e15] in patients with COPD. In our studies,
UMEC/VI also decreased air trapping and lung hyperinfla-
tion versus FP/SAL, as FVC endpoints and trough IC (only
evaluated in DB2114930) were significantly improved. Our
findings on IC confirm other reports that LAMA/LABA
880 J.F. Donohue et al.combinations [23] improve this endpoint, as does FP/SAL
[24,25]. Thus, another potential clinical benefit of UMEC/VI
is the reduction of hyperinflation. Overall, there were no
new safety concerns with either combination in these
studies. The safety findings in both studies were similar to
those reported in previous studies of UMEC/VI [8e11] and
FP/SAL [13e15].
Both studies had several strengths including: direct
comparison of UMEC/VI at the approved clinical regimen
with a commonly used ICS-based treatment; recruitment of
approximately equal proportions of patients with moderate
or severe COPD to each treatment; the use of dyspnea score
as an inclusion criterion to ensure patients were symp-
tomatic at baseline; large sample sizes; high treatment
compliance; and avoidance of multiple comparisons and
multiplicity issues by applying statistical hierarchy meth-
odology. Two potential limitations were the restriction of
recruitment to patients with GOLD II and III COPD (potential
benefits of UMEC/VI versus FP/SAL are unstudied in mild
and very severe COPD), and the short therapy duration.
Conclusions
In patients with symptomatic moderate-to-severe COPD
and infrequent COPD exacerbations, once-daily UMEC/VI
62.5/25 mcg demonstrated statistically significant and
clinically meaningful improvements in lung function versus
twice-daily FP/SAL 250/50 mcg over 12 weeks that were
consistent across the two studies. Overall, the incidence of
AEs was similar between treatment groups. Our findings
suggest that treatment with a steroid-sparing LAMA/LABA
combination, such as UMEC/VI, may provide greater bene-
fits in lung function than an ICS/LABA combination, such as
FP/SAL. Further studies are required to compare the rela-
tive effects of UMEC/VI and FP/SAL on COPD exacerbations.
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